of 0.34-149.10 µM. The inhibition percentage of VEGFR-2 was measured for all the compounds and found to be in the range of 90.09-20.44%. The promising compounds 8, 12, 13, 16 and 17 were selected to measure their possible multikinase inhibitory activity against VEGFR-2 and EGFR. IC50 of the promising compounds were in the range of 247-793 nM for VEGFR-2 in reference to sunitinib (IC50 320 nM), and 369-725 nM
多靶点治疗被认为是成功的癌症治疗方法。通过杂交策略开发小分子多激酶
抑制剂可以提供高效且选择性的抗癌药。设计并合成了N-烷基-2-[(4-氧代-3-(4-
氨磺酰基苯基)-3,4-二氢
喹唑啉-2-基)
硫代]乙酰胺衍
生物5-18的文库。筛选合成的化合物对
MDA-MB-231乳腺癌
细胞系的细胞毒活性,显示IC50为0.34-149.10 µM。测量所有化合物的V
EGFR-2抑制百分数,发现其在90.09-20.44%的范围内。选择有希望的化合物8、12、13、16和17来测量其针对V
EGFR-2和
EGFR的可能的多激酶抑制活性。相对于
舒尼替尼(IC50 320 nM),V
EGFR-2的有希望化合物的IC50为247-793 nM,相对于
厄洛替尼(IC50 568 nM),
EGFR的IC50为369-725 nM。化合物12和13分别显示出对V
EGFR-2和
EGFR最有效的活性。测量12和13对MC